Cargando…

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma

Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conroy, Michael, Borad, Mitesh J, Bryce, Alan H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613928/ https://www.ncbi.nlm.nih.gov/pubmed/28959512 http://dx.doi.org/10.7759/cureus.1517

Ejemplares similares

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea
por: Kim, Se Ik, et al.
Publicado: (2022)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Increased Intragenic IGF2 Methylation is Associated with Repression of Insulator Activity and Elevated Expression in Serous Ovarian Carcinoma
por: Huang, Zhiqing, et al.
Publicado: (2013)

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer
por: Song, Li, et al.
Publicado: (2019)

Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
por: Heredia-Soto, Victoria, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

Stage, treatment and survival of low‐grade serous ovarian carcinoma in the Netherlands: A nationwide study
por: De Decker, Koen, et al.
Publicado: (2023)

Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases
por: Pejovic, Tanja, et al.
Publicado: (2022)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Metastatic serous endometrial carcinoma to the ureter
por: Sahl, Jessa W., et al.
Publicado: (2021)

Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
por: Romani, Chiara, et al.
Publicado: (2020)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
por: Rundo, Leonardo, et al.
Publicado: (2022)

Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
por: Mairinger, Elena, et al.
Publicado: (2023)

Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer
por: Chang, Yu-Chan, et al.
Publicado: (2022)

Testicular papillary serous carcinoma of ovarian type, a rare case report, however an important timely diagnostic issue
por: Zeighami, Shahryar, et al.
Publicado: (2020)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
por: Koc, Zeynep C., et al.
Publicado: (2023)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis
por: Zhang, Yanna, et al.
Publicado: (2022)

Nomograms of Combining MRI Multisequences Radiomics and Clinical Factors for Differentiating High-Grade From Low-Grade Serous Ovarian Carcinoma
por: Li, Cuiping, et al.
Publicado: (2022)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer
por: Ohman, Anders W., et al.
Publicado: (2014)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
Publicado: (2022)

Comparative analysis between high-grade serous ovarian cancer and healthy ovarian tissues using single-cell RNA sequencing
por: Zhang, Xiao, et al.
Publicado: (2023)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)

Characterizing high-grade serous papillary carcinoma of tunica vaginalis
por: Qu, Liang G., et al.
Publicado: (2019)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_21g6je4oit8timkav6m5fr5j21